Emicizumab-kxwh Subcutaneous and Rosiglitazone Maleate

• Generic Name: emicizumab
• Dosage Forms: n.a.
• Other Brand Names: Hemlibra, Hemlibra 105 mg/07 mL, Hemlibra 60 mg/04 mL

Emicizumab-kxwh injection is used to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital Factor VIII deficiency).

Emicizumab-kxwh is available only with your doctor's prescription.

• Generic Name: rosiglitazone
• Dosage Forms: n.a.
• Other Brand Names: Avandia

Used as monotherapy or in combination with a sulfonylurea, metformin, or a sulfonylurea and metformin as an adjunct to diet and exercise for the management of type 2 (noninsulin-dependent) diabetes mellitus (NIDDM).

May be added to glyburide/metformin fixed-combination therapy if hyperglycemia is not adequately controlled with the fixed combination.

May be used in combination with repaglinide if hyperglycemia is not adequately controlled with repaglinide monotherapy.

May use fixed combination of rosiglitazone/metformin (Avandamet) when treatment with rosiglitazone and metformin is appropriate.

May use fixed combination of rosiglitazone/glimepiride (Avandaryl) when treatment with rosiglitazone and glimepiride is appropriate.

Metformin is the preferred initial oral antidiabetic agent for patients with type 2 diabetes mellitus. Thiazolidinediones are one of several second-line agents used with other oral antidiabetic agents (e.g., metformin) in patients who are inadequately controlled on their current oral therapy. Because of potential for serious adverse effects, American Diabetes Association (ADA) recommends that clinicians carefully weigh the potential risks and benefits of thiazolidinediones versus other second-line agents (i.e., insulin, sulfonylureas).

Use in combination with insulin not recommended.

Because endogenous insulin is required for activity, not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.